<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35218882</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1464-3405</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Bioorganic &amp; medicinal chemistry letters</Title>
          <ISOAbbreviation>Bioorg Med Chem Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rationalizing the binding and α subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.</ArticleTitle>
        <Pagination>
          <StartPage>128637</StartPage>
          <MedlinePgn>128637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2022.128637</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0960-894X(22)00113-5</ELocationID>
        <Abstract>
          <AbstractText>The pharmacological actions exerted by benzodiazepines are dependent on the discrete α protein subunits of the γ-aminobutyric acid type A receptor (GABA<sub>A</sub> R). Recent developments via a cryo-EM structure of the α1β3γ2L GABA<sub>A</sub> R ion channel provide crucial insights into ligand efficacy and binding affinity at this subtype. We investigated the molecular interactions of diazepam and alprazolam bound GABA<sub>A</sub> R structures (6HUP and 6HUO) to determine key binding interaction domains. A halogen bond between the chlorine atoms of diazepam and alprazolam with the group on the backbone of the α1 histidine amino acid 102 is important to the positive allosteric modulatory actions of diazepam and alprazolam in the α1β3γ2L GABA<sub>A</sub> R ion channel. In order to gain insight into α subtype selectivity we designed and synthesized close structural analogs of diazepam and alprazolam. These compounds were then docked into the recently publish cryo-EM structures of GABA<sub>A</sub> Rs (6HUP and 6HUO). This modeling along with radio-ligand binding data resulted in the conclusion that the non-classical bioisosteric replacement of the chlorine atom at C7 with an ethinyl group (compound 5) resulted in an 11-fold gain in α5 binding selectivity over the α1 subtype. Moreover, the potency of compound 5 resulted in a ligand with less sedation than diazepam, while still maintaining the same anxiolytic potency. These modeling data extend our understanding of the structural requirements for α-subtype-selective compounds that can be utilized to achieve improved medical treatments. It is clear that the ethinyl group in place of a halogen atom decreases the affinity and efficacy of benzodiazepines and imidazodiazepines at α1 subtypes, which results in less sedation and ataxia.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Golani</LastName>
            <ForeName>Lalit K</ForeName>
            <Initials>LK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeunus Mian</LastName>
            <ForeName>Md</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmed</LastName>
            <ForeName>Taukir</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pandey</LastName>
            <ForeName>Kamal P</ForeName>
            <Initials>KP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mondal</LastName>
            <ForeName>Prithu</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharmin</LastName>
            <ForeName>Dishary</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rezvanian</LastName>
            <ForeName>Sepideh</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Witkin</LastName>
            <ForeName>Jeffrey M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Laboratory of Antiepileptic Drug Discovery, St. Vincent's Hospital, Indianapolis, IN USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cook</LastName>
            <ForeName>James M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA. Electronic address: capncook@uwm.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Bioorg Med Chem Lett</MedlineTA>
        <NlmUniqueID>9107377</NlmUniqueID>
        <ISSNLinking>0960-894X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4R7X1O2820</RegistryNumber>
          <NameOfSubstance UI="D002713">Chlorine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
          <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="Y">Benzodiazepines</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002713" MajorTopicYN="N">Chlorine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011963" MajorTopicYN="Y">Receptors, GABA-A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Benzodiazepines</Keyword>
        <Keyword MajorTopicYN="Y">Bioisostere</Keyword>
        <Keyword MajorTopicYN="Y">Halogen bond</Keyword>
        <Keyword MajorTopicYN="Y">Molecular docking</Keyword>
        <Keyword MajorTopicYN="Y">Protein ligand interactions</Keyword>
        <Keyword MajorTopicYN="Y">γ-Aminobutyric acid type A receptor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35218882</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bmcl.2022.128637</ArticleId>
        <ArticleId IdType="pii">S0960-894X(22)00113-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
